Myostatin Level in CRF Patients with and Without HBV and Its Correlation with Sarcopenia

Abstract

Chronic kidney disease (CKD) is a public health problem, with a prevalence that is steadily increasing. The high prevalence rate of CKD is explained by the increased proportion of elderly people, hypertension, and diabetes in the context of a longer life expectancy. CKD reflects the occurrence of a premature aging process, similar to other chronic diseases. Muscle mass is an important factor in determining the prognosis of these patients. Muscle wasting is an important feature in the syndrome of protein-energy wasting (PEW) present in patients with chronic kidney disease (CKD), which undoubtedly contributes to the increased mortality of this patient population. Although multiple catabolic or anabolic alterations have been shown to contribute to the mechanisms of CKD-related muscle wasting, the molecular pathways have not been fully elucidated. Myostatin, also called growth/differentiation factor-8, belongs to a transforming growth factor-β superfamily and regulates the synthesis and degradation of skeletal muscle protein. Myostatin, which is mainly produced in muscle, suppresses growth in skeletal muscle and its inhibition leads to muscle hypertrophy. Myostatin levels are increased in patients with chronic skeletal muscle wasting diseases, such as CKD, chronic liver disease, or chronic heart failure